Viktor Roschke News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Neuraly has announced that its investigational NLY01 did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated Parkinson’s disease.According to a company release, NLY01 is a long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor agonist. In an ongoing phase 2 trial, NLY01 did not achieve statistically significant change from

Published: Apr 28, 2021   Neuronal viability was preserved, resulting in improved spatial learning and memory   GAITHERSBURG, Md.--(BUSINESS WIRE)-- Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced publication in the peer-reviewed journal Acta Neuropathologica Communications of preclinical data that contributed to the therapeutic rationale for clinical evaluation of NLY01 in Alzheimer’s and Parkinson’s diseases. The research was conducted in collaboration with Dr. Ted Dawson’s lab at the Johns Hop...